Human XL Cytokine Luminex® Performance Panel Premixed Kit
Human XL Cytokine Luminex® Performance Panel Premixed Kit Summary
| Assay Type | bead-based multiplex assay for the Luminex® platform |
| Format | 1 x 96-well microplate and antibody-coated beads |
| Analytes Detected | Please see analyte list in assay customization tool below. |
| Performance Validation | Luminex Assays are validated for use with cell culture supernatants, plasma and serum. All Luminex assays are tested for sensitivity, intra-assay precision, inter-assay precision and to ensure assay linearity for validated sample types. Antibody pairs are selected and tested to confirm the parallel detection of natural and recombinant standard protein and to ensure the accurate determination of target analytes within biological samples. Assays for each target analyte are screened against all target analytes to confirm low antibody cross-reactivity. View Luminex High Performance Human XL validation data. |
Not finding your analyte of interest? View our complete Luminex offering in the full version of our Luminex Assay Customization Tool. We also offer Custom Luminex Services.
Precision
|
Intra-Assay Precision - is generated from the mean of the %CV's from 40 reportable results across two different concentrations of analytes in a single serum assay Inter-Assay Precision - is generated from the mean of the %CV's across two different concentrations of analytes across 25 different serum assays. |
||
| n=40 (20x2 levels) | n=25 | |
|---|---|---|
| Analyte | Intra-Assay (%CV) | Inter-Assay (%CV) |
| B7-H1/PD-L1 | 1.8% | 11.3% |
| CCL11/Eotaxin | 3.2% | 10.0% |
| CCL19/MIP-3beta | 2.2% | 9.7% |
| CCL2/MCP-1 | 1.4% | 8.9% |
| CCL20/MIP-3 alpha | 2.4% | 9.9% |
| CCL3/MIP-1alpha | 1.5% | 7.3% |
| CCL4/MIP-1beta | 3.0% | 9.6% |
| CD40 Ligand | 3.3% | 10.6% |
| CXCL1/GRO alpha | 1.0% | 8.0% |
| CXCL10/IP-10 | 2.1% | 8.8% |
| CXCL2/GRO beta | 1.2% | 8.8% |
| CXCL8/IL-8 | 1.8% | 9.0% |
| EGF | 3.0% | 9.6% |
| FGF-basic | 4.2% | 12.6% |
| Flt-3 ligand | 2.5% | 10.1% |
| G-CSF | 1.8% | 10.2% |
| GM-CSF | 3.1% | 10.3% |
| Granzyme B | 1.8% | 11.0% |
| IFN-alpha | 2.9% | 9.9% |
| IFN-beta | 3.0% | 11.0% |
| IFN-gamma | 2.8% | 10.4% |
| IL-10 | 3.3% | 9.0% |
| IL-12 p70 | 2.3% | 10.5% |
| IL-13 | 1.6% | 9.7% |
| IL-15 | 2.4% | 9.9% |
| IL-17A | 2.5% | 11.2% |
| IL-17E/IL-25 | 1.7% | 9.2% |
| IL-1alpha | 3.0% | 10.4% |
| IL-1beta | 2.3% | 10.0% |
| IL-1ra | 2.1% | 10.3% |
| IL-2 | 2.2% | 9.2% |
| IL-3 | 2.5% | 10.1% |
| IL-33 | 2.4% | 12.3% |
| IL-4 | 3.2% | 9.7% |
| IL-5 | 2.2% | 12.0% |
| IL-6 | 2.6% | 9.8% |
| IL-7 | 2.5% | 9.8% |
| PDGF-AA | 2.8% | 15.5% |
| PDGF-AB/BB | 2.4% | 12.4% |
| RANTES | 4.7% | 17.4% |
| TGF-alpha | 3.0% | 9.8% |
| TNF-alpha | 2.2% | 8.7% |
| TRAIL | 2.0% | 10.3% |
| VEGF | 2.6% | 10.3% |
Accuracy
|
Linearity - The data represents mean spiked or natural linearity in serum matrix samples. Samples with natural linearity are marked with an asterisk. Spike Recovery - The data represents mean percent recovery of spiked standards ranging from low, medium, and high concentration in serum matrix samples. |
||||
| Linearity | Spiked Recovery |
|||
|---|---|---|---|---|
| Analyte | N | Average % | N | Average % |
|
*Natural linearity |
||||
| B7-H1/PD-L1 | 4 | 106% | 4 | 109% |
| CCL11/Eotaxin | 4 | 92% | 4 | 107% |
| CCL19/MIP-3beta | 4 | 123% | 4 | 95% |
| CCL2/MCP-1 | 4* | 82% | High endogenous | |
| CCL20/MIP-3 alpha | 4 | 107% | 4 | 99% |
| CCL3/MIP-1alpha | 4 | 77% | 4 | 139% |
| CCL4/MIP-1beta | 4 | 103% | 4 | 111% |
| CD40 Ligand | 4 | 113% | 4 | 100% |
| CXCL1/GRO alpha | 4 | 80% | High endogenous | |
| CXCL10/IP-10 | 3 | 110% | High endogenous | |
| CXCL2/GRO beta | 4* | 114% | 3 | 106% |
| CXCL8/IL-8 | 4 | 118% | 4 | 96% |
| EGF | 4* | 110% | 4 | 106% |
| FGF-basic | 4 | 161% | 3 | 80% |
| Flt-3 ligand | 4 | 102% | 4 | 109% |
| G-CSF | 4 | 209% | 4 | 43% |
| GM-CSF | 4 | 96% | 4 | 110% |
| Granzyme B | 4 | 99% | 4 | 118% |
| IFN-alpha | 3 | 98% | 4 | 101% |
| IFN-beta | 4 | 148% | 4 | 69% |
| IFN-gamma | 4 | 97% | 4 | 112% |
| IL-10 | 4 | 111% | 4 | 104% |
| IL-12 p70 | 4 | 106% | 4 | 108% |
| IL-13 | 4 | 112% | 4 | 103% |
| IL-15 | 3 | 88% | 3 | 89% |
| IL-17A | 4 | 110% | 4 | 106% |
| IL-17E/IL-25 | 4 | 122% | 4 | 87% |
| IL-1alpha | 4 | 143% | 4 | 80% |
| IL-1beta | 4 | 107% | 4 | 99% |
| IL-1ra | 4* | 100% | 4 | 145% |
| IL-2 | 4 | 105% | 4 | 102% |
| IL-3 | 4 | 123% | 4 | 88% |
| IL-33 | 4 | 93% | 4 | 110% |
| IL-4 | 3 | 127% | 3 | 77% |
| IL-5 | 3 | 113% | 3 | 81% |
| IL-6 | 3 | 124% | 3 | 90% |
| IL-7 | 4 | 113% | 4 | 96% |
| PDGF-AA | 4* | 90% | High endogenous | |
| PDGF-AB/BB | 4* | 96% | High endogenous | |
| RANTES | 4* | 96% | High endogenous | |
| TGF-alpha | 4 | 117% | 4 | 96% |
| TNF-alpha | 4 | 117% | 4 | 69% |
| TRAIL | 3 | 123% | 4 | 88% |
| VEGF | 4 | 103% | 4 | 109% |
Assays for the Luminex platform are offered as High Performance Assays or Assays. The Luminex High Performance Assays are fully validated panels with a focused selection of analytes. They are available in We Mix, You Mix, and Predetermined formats. The Luminex Assays allows for the maximum number of analytes in a multiplex and is supplied as a premixed kit. View a table comparing the features and benefits of these bead-based multiplex assays.
Scientific Data
View Larger
Human XL Cytokine Performance Luminex Panel Serum Sample Values Serum samples from 20 apparently healthy individuals were run on the Human XL Cytokine Luminex High Performance Panel and sample values plotted. Minimum and maximum values shown by exterior lines, the box represents the 1st and 3rd quartiles with the center line representing the median.
Product Datasheets
Citations for Human XL Cytokine Luminex® Performance Panel Premixed Kit
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
22
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases
Authors: Wiedemann, A;Lhomme, E;Huchon, M;Foucat, E;Bérerd-Camara, M;Guillaumat, L;Yaradouno, M;Tambalou, J;Rodrigues, C;Ribeiro, A;Béavogui, AH;Lacabaratz, C;Thiébaut, R;Richert, L;Lévy, Y;Prevac study team, ;
Nature communications
Species: Human
Sample Types: Cell Culture Supernates
-
Neutrophil activation and clonal CAR-T re-expansion underpinning cytokine release syndrome during ciltacabtagene autoleucel therapy in multiple myeloma
Authors: Yang, S;Xu, J;Dai, Y;Jin, S;Sun, Y;Li, J;Liu, C;Ma, X;Chen, Z;Chen, L;Hou, J;Mi, JQ;Chen, SJ;
Nature communications
Species: Human
Sample Types: Serum
-
ADAR1 protects pulmonary macrophages from sepsis-induced pyroptosis and lung injury through miR-21/A20 signaling
Authors: Zhao, X;Xie, J;Duan, C;Wang, L;Si, Y;Liu, S;Wang, Q;Wu, D;Wang, Y;Yin, W;Zhuang, R;Li, J;
International journal of biological sciences
Species: Human
Sample Types: Serum
-
Novel inflammatory mediator profile observed during pediatric heart surgery with cardiopulmonary bypass and continuous ultrafiltration
Authors: Bierer, J;Stanzel, R;Henderson, M;Sett, S;Sapp, J;Andreou, P;Marshall, JS;Horne, D;
Journal of translational medicine
Species: Human
Sample Types: Plasma
-
The Influence of Comorbidities on Chemokine and Cytokine Profile in Obstructive Sleep Apnea Patients: Preliminary Results
Authors: M Chaszczews, K Górna, K Bogunia-Ku, A Brzecka, M Kosacka
Journal of Clinical Medicine, 2023-01-19;12(3):.
Species: Human
Sample Types: Serum
-
Association of miR-144 levels in the peripheral blood with COVID-19 severity and mortality
Authors: A Madè, S Greco, M Vausort, M Miliotis, E Schordan, S Baksi, L Zhang, E Baryshniko, M Ranucci, R Cardani, G Fagherazzi, M Ollert, S Tastsoglou, G Vatsellas, A Hatzigeorg, H Firat, Y Devaux, F Martelli
Scientific Reports, 2022-11-21;12(1):20048.
Species: Human
Sample Types: Serum
-
Intestinal Injury Biomarkers Predict Mortality in Pediatric Severe Malaria
Authors: ML Sarangam, R Namazzi, D Datta, C Bond, CPB Vanderpool, RO Opoka, CC John, AL Conroy
MBio, 2022-09-07;0(0):e0132522.
Species: Human
Sample Types: Serum
-
Intestinal fatty acid binding protein (I-FABP) and CXC3L1 evaluation as biomarkers for patients at high-risk for coeliac disease in Johannesburg, South Africa
Authors: A Gandini, T De Maayer, C Munien, K Bertrand, R Cairns, A Mayne, MP Gededzha, ES Mayne
Cytokine, 2022-07-13;157(0):155945.
Species: Human
Sample Types: Serum
-
A novel platform for attenuating immune hyperactivity using EXO-CD24 in Covid-19 and beyond
Authors: S Shapira, MB Shimon, M Hay-Levi, G Shenberg, G Choshen, L Bannon, M Tepper, D Kazanov, J Seni, S Lev-Ari, M Peer, D Boubas, J Stebbing, S Tsiodras, N Arber
Oncogene, 2022-07-13;0(0):e15997.
Species: Human
Sample Types: Cell Culture Supernates
-
Combining adoptive NK cell infusion with a dopamine-releasing peptide reduces senescent cells in aged mice
Authors: Z Bai, P Yang, F Yu, Z Li, Z Yao, J Martinez, M Li, H Xu
Cell Death & Disease, 2022-04-05;13(4):305.
Species: Human
Sample Types: Cell Culture Supernates
-
Severe COVID-19 infection is associated with aberrant cytokine production by infected lung epithelial cells rather than by systemic immune dysfunction
Authors: T Gajewski, S Rouhani, J Trujillo, A Pyzer, J Yu, J Fessler, A Cabanov, E Higgs, K Cron, Y Zha, Y Lu, J Bloodworth, M Abasiyanik, S Okrah, B Flood, K Hatogai, M Leung, A Pezeshk, L Kozloff, R Reschke, G Strohbehn, CS Chervin, M Kumar, S Schrantz, ML Madariaga, K Beavis, KT Yeo, R Sweis, J Segal, S Tay, E Izumchenko, J Mueller, L Chen
Research square, 2021-11-24;0(0):.
Species: Human
Sample Types: Serum
-
Comparative expression of pro-inflammatory and apoptotic biosignatures in chronic HBV-infected patients with and without liver cirrhosis
Authors: M Barathan, B Riazalhoss, T Iyadorai, KM Vellasamy, J Vadivelu, LY Chang, AK Zulpa, M Larsson, EM Shankar, R Mohamed
Microbial pathogenesis, 2021-10-05;161(0):105231.
Species: Human
Sample Types: Plasma
-
A high-throughput microfluidic bilayer co-culture platform to study endothelial-pericyte interactions
Authors: MT Rogers, AL Gard, R Gaibler, TJ Mulhern, R Strelnikov, H Azizgolsha, BP Cain, BC Isenberg, NJ Haroutunia, NE Raustad, PM Keegan, MP Lech, L Tomlinson, JT Borenstein, JL Charest, C Williams
Scientific Reports, 2021-06-09;11(1):12225.
Species: Human
Sample Types: Cell Culture Supernates
-
Integrating longitudinal clinical laboratory tests with targeted proteomic and transcriptomic analyses reveal the landscape of host responses in COVID-19
Authors: Y Tan, W Zhang, Z Zhu, N Qiao, Y Ling, M Guo, T Yin, H Fang, X Xu, G Lu, P Zhang, S Yang, Z Fu, D Liang, Y Xie, R Zhang, L Jiang, S Yu, J Lu, F Jiang, J Chen, C Xiao, S Wang, S Chen, XW Bian, H Lu, F Liu, S Chen
Cell Discovery, 2021-06-08;7(1):42.
Species: Human
Sample Types: Serum
-
Direct effects of mast cell proteases, tryptase and chymase, on bronchial epithelial integrity proteins and anti-viral responses
Authors: S Ramu, H Akbarshahi, S Mogren, F Berlin, S Cerps, M Menzel, M Hvidtfeldt, C Porsbjerg, L Uller, CK Andersson
BMC immunology, 2021-06-02;22(1):35.
Species: Human
Sample Types: Cell Culture Supernates
-
Role of serum CXCL9 and CXCL13 in predicting infection after kidney transplant: A STROBE study
Authors: L Yan, YM Li, Y Li, YJ Bai, ZL Wan, JW Fan, LM Luo, LL Wang, YY Shi
Medicine, 2021-03-19;100(11):e24762.
Species: Human
Sample Types: Serum
-
Wound fluid under occlusive dressings from diabetic patients show an increased angiogenic response and fibroblast migration
Authors: MK Cerny, A Wiesmeier, U Hopfner, C Topka, W Zhang, HG Machens, M van Griens, N Broer, D Duscher
Journal of tissue viability, 2021-03-05;0(0):.
Species: Human
Sample Types: Serum
-
Novel TLR 7/8 agonists for improving NK cell mediated antibody-dependent cellular cytotoxicity (ADCC)
Authors: V Khanna, H Kim, W Zhang, P Larson, M Shah, TS Griffith, D Ferguson, J Panyam
Scientific Reports, 2021-02-08;11(1):3346.
Species: Human
Sample Types: Cell Culture Supernates
-
Co-expression of NMDA-receptor subunits NR1, NR2A, and NR2B in dysplastic neurons of teratomas in patients with paraneoplastic NMDA-receptor-encephalitis: a retrospective clinico-pathology study of 159 patients
Authors: XY Jiang, S Lei, L Zhang, X Liu, MT Lin, I Blumcke, YS Piao, D Zhou, JM Li
Acta Neuropathol Commun, 2020-08-08;8(1):130.
Species: Human
Sample Types: CSF
-
Long-lasting severe immune dysfunction in Ebola virus disease survivors
Authors: A Wiedemann, E Foucat, H Hocini, C Lefebvre, BP Hejblum, M Durand, M Krüger, AK Keita, A Ayouba, S Mély, JC Fernandez, A Touré, S Fourati, C Lévy-March, H Raoul, E Delaporte, L Koivogui, R Thiébaut, C Lacabaratz, Y Lévy
Nat Commun, 2020-07-24;11(1):3730.
Species: Human
Sample Types: Serum
-
Multiple cytokine analyses of aqueous humor from the patients with retinitis pigmentosa
Authors: B Lu, H Yin, Q Tang, W Wang, C Luo, X Chen, X Zhang, K Lai, J Xu, X Chen, K Yao
Cytokine, 2019-12-03;127(0):154943.
Species: Human
Sample Types: Aqueous Humor
-
Synergistic Effects of Weightlessness, Isoproterenol, and Radiation on DNA Damage Response and Cytokine Production in Immune Cells
Authors: M Moreno-Vil, AH Feiveson, S Krieger, A Kay Brinda, G von Scheve, A Bürkle, B Crucian, H Wu
Int J Mol Sci, 2018-11-21;19(11):.
Species: Human
Sample Types: Cell Culture Supernates
FAQs
-
Does Catalog # FCSTM18 contain Thimerasol?
This kit does not contain Thimerasol. R&D Systems transitioned away from this preservative in 2008. Proclin 300 is now used.
Reviews for Human XL Cytokine Luminex® Performance Panel Premixed Kit
Average Rating: 5 (Based on 9 Reviews)
Have you used Human XL Cytokine Luminex® Performance Panel Premixed Kit?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
CRS in house method development using PBMCs.
CRS assay method development
T cell cytokine release signature with mAb stimulation.
T cell responses when co-incubate with a cancer cell with mAb stimulation.
screening a disease and healthy donor serum
Cytokine Release Assay using healthy donor PBMC stimulated with different mAbs
